Board to consider Interim Dividend
Suven Life Sciences Ltd has informed BSE that a Board Meeting of the Company will be held on February 01, 2017, inter alia, to consider and take on record the following matter(s):1. To consider and approve the Un-audited Financial Results of the Company under Ind AS for the quarter and nine months ended December 31, 20162. To consider declaration of Interim Dividend, if any, for the financial year 2016-17 and related matters etc. and... Suven Life Sciences secures a Product Patent in Australia
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated January 23, 2017 titled "Suven Life Sciences secures a Product Patent in Australia". Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Suven Life Sciences Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Suven Inc is presenting at Biotech Showcase 2017 on 11th January and attending 35th Annual J.P. Morgan Healthcare Conference at San Francisco
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated January 11, 2017 titled "Suven Inc is presenting at Biotech Showcase 2017 on 11th January and attending 35th Annual J.P. Morgan Healthcare Conference at San Francisco". Shareholding for the Period Ended December 31, 2016
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Company news
Suven Life Sciences has informed the exchanges that it has received one product patent each in Eurasia and Norway. These patents in Eurasia and Norway will be valid through 2032 and 2025,... Suven Life Sciences secures two (2) Product Patents in Eurasia and Norway
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated January 03, 2017 titled "Suven Life Sciences secures two (2) Product Patents in Eurasia and Norway". Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during December 8-10, 2016 at San Diego, USA
Suven Life Sciences Ltd has informed BSE regarding a Press Release dated December 08, 2016 titled "Suven to Present at 9th CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) Conference held during December 8-10, 2016 at San Diego, USA". Suven Life gets patent for neuro-degenerative drug
Suven Life Sciences has been granted a patent in India for a drug used for the treatment of neuro-degenerative diseases. In a BSE filing today, Suven Life said it has been granted one product...